# ART First-line Treatment Durability in Russia

> **NCT04253119** · — · COMPLETED · sponsor: **MSD Pharmaceuticals LLC** · enrollment: 536 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Antiretroviral/Anti HIV

## Key facts

- **NCT ID:** NCT04253119
- **Lead sponsor:** MSD Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-26
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 536 (ACTUAL)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04253119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04253119, "ART First-line Treatment Durability in Russia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04253119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*